Transparency, Power, and Influence in the Pharmaceutical Industry evaluates the progress made in holding the pharmaceutical industry to account through greater transparency.
Transparency, Power, and Influence in the Pharmaceutical Industry evaluates the progress made in holding the pharmaceutical industry to account through greater transparency.
Edited by Katherine Fierlbeck, Janice Graham, and Matthew Herder
Inhaltsangabe
1. Introduction Katherine Fierlbeck, Janice Graham, and Matthew Herder 2. Transparency, Pharmaceuticals, and the Problem of Policy Change Katherine Fierlbeck 3. Data Transparency and Pharmaceutical Regulation in Europe: Road to Damascus, or Room without a View? Courtney Davis, Shai Mulinari, and Tom Jefferson 4. FDA and Health Canada: Similar Origins, yet Divergent Paths and Approaches to Transparency Margaret McCarthy and Joe Ross 5. Clinical Trial Data Transparency in Canada: Mapping the Progress from Laggard to Leader Marc-André Gagnon, Matthew Herder, Janice Graham, Katherine Fierlbeck, and Anna Danyliuk 6. How Clinical Study Information Transparency Can Fail to Serve Its Purpose, and How the Essential Medicines Concept Can Help Nav Persaud 7. Speak No Secrets: (Non)transparency in Health Canada’s Communications about Pharmaceutical Regulation Joel Lexchin 8. Economic Ghost-Management in the Pharmaceutical Sector Marc-Andre Gagnon 9. Balancing the Privacy Rights of Research Participants with the Public Interest in Clinical Drug Trials Data in the Context of Rare Diseases Kanksha Mahadevia Ghimire and Trudo Lemmens 10. The European Registration of the Pandemic Influenza Vaccine Pandemrix: A Case Study of the Consequences of Poor Clinical Data Transparency Tom Jefferson 11. Sharing Data and Ideas for Good Health: How Researchers Can Sustain an Ethical and Transparent Health System Rita Banzi 12. Conclusion Katherine Fierlbeck, Janice Graham, and Matthew Herder
1. Introduction Katherine Fierlbeck, Janice Graham, and Matthew Herder 2. Transparency, Pharmaceuticals, and the Problem of Policy Change Katherine Fierlbeck 3. Data Transparency and Pharmaceutical Regulation in Europe: Road to Damascus, or Room without a View? Courtney Davis, Shai Mulinari, and Tom Jefferson 4. FDA and Health Canada: Similar Origins, yet Divergent Paths and Approaches to Transparency Margaret McCarthy and Joe Ross 5. Clinical Trial Data Transparency in Canada: Mapping the Progress from Laggard to Leader Marc-André Gagnon, Matthew Herder, Janice Graham, Katherine Fierlbeck, and Anna Danyliuk 6. How Clinical Study Information Transparency Can Fail to Serve Its Purpose, and How the Essential Medicines Concept Can Help Nav Persaud 7. Speak No Secrets: (Non)transparency in Health Canada’s Communications about Pharmaceutical Regulation Joel Lexchin 8. Economic Ghost-Management in the Pharmaceutical Sector Marc-Andre Gagnon 9. Balancing the Privacy Rights of Research Participants with the Public Interest in Clinical Drug Trials Data in the Context of Rare Diseases Kanksha Mahadevia Ghimire and Trudo Lemmens 10. The European Registration of the Pandemic Influenza Vaccine Pandemrix: A Case Study of the Consequences of Poor Clinical Data Transparency Tom Jefferson 11. Sharing Data and Ideas for Good Health: How Researchers Can Sustain an Ethical and Transparent Health System Rita Banzi 12. Conclusion Katherine Fierlbeck, Janice Graham, and Matthew Herder
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
